Ahmad Sarwat B, Menaker Jay, Kufera Joseph, OʼConnor James, Scalea Thomas M, Stein Deborah M
From the Department of Surgery, University of Maryland School of Medicine (S.B.A., J.M., J.O., T.M.S., D.M.S.); R Adams Cowley Shock Trauma Center, Baltimore, Maryland (J.M., J.K., J.O., T.M.S., D.M.S.).
J Trauma Acute Care Surg. 2017 Mar;82(3):587-591. doi: 10.1097/TA.0000000000001352.
The use of extracorporeal membrane oxygenation (ECMO) for acute respiratory failure after injury is controversial and poorly described.
We reviewed our single-center experience with use of ECMO from January 2006 to November 2015 at a Level 1 primary adult resource center for trauma to determine the association of in-hospital mortality with patient demographics and clinical variables.
Forty-six patients were treated with ECMO. Patients requiring venoarterial ECMO (n = 7) were excluded. Thirty-nine (85%) were cannulated for venovenous ECMO. Of these, 44% patients survived to discharge. Median age was 28 years. Survivors had a lower BMI and PaCO2 at time of cannulation. Nonsurvivors were more severely injured (median Injury Severity Score, 41 vs. 25; p = 0.03), had a lower arterial pH on arrival, and a shorter length of stay (11 vs. 41 days; p = 0.006). Neither mechanism of injury nor indication for ECMO was associated with mortality. Forty-one percent developed at least one ECMO-related complication, but this was not associated with mortality. Ninety-four percent of the survivors were anticoagulated with heparin versus 55% of nonsurvivors (p = 0.01). Median Injury Severity Score and presence of TBI were not significantly different between survivors and nonsurvivors who were anticoagulated.
The use of venovenous ECMO for acute lung injury after trauma should be considered in special patient populations. Ability to tolerate systemic anticoagulation was associated with improved survival.
Therapeutic study, level V.
体外膜肺氧合(ECMO)用于损伤后急性呼吸衰竭存在争议且描述较少。
我们回顾了2006年1月至2015年11月在一家一级成人创伤主要资源中心使用ECMO的单中心经验,以确定院内死亡率与患者人口统计学和临床变量之间的关联。
46例患者接受了ECMO治疗。需要静脉-动脉ECMO(n = 7)的患者被排除。39例(85%)接受了静脉-静脉ECMO插管。其中,44%的患者存活至出院。中位年龄为28岁。存活者插管时的BMI和PaCO2较低。非存活者受伤更严重(中位损伤严重度评分,41对25;p = 0.03),入院时动脉pH值较低,住院时间较短(11天对41天;p = 0.006)。损伤机制和ECMO指征均与死亡率无关。41%的患者发生了至少一种与ECMO相关的并发症,但这与死亡率无关。94%的存活者使用肝素抗凝,而非存活者为55%(p = 0.01)。在接受抗凝的存活者和非存活者之间,中位损伤严重度评分和创伤性脑损伤的存在无显著差异。
对于特殊患者群体,应考虑使用静脉-静脉ECMO治疗创伤后急性肺损伤。耐受全身抗凝的能力与生存率提高相关。
治疗性研究,V级。